Predictors of Transition from Mild Cognitive Impairment to Normal Cognition and Dementia

Jiage Gao1,2, Lin Liu1,2, Zifeng Yang1,2

  • 1Institute of Psychological and Brain Sciences, Liaoning Normal University, Dalian 116029, China.

Insights

Mild cognitive impairment (MCI) can reverse in some individuals. Higher education, larger hippocampal volume, and better daily function predict MCI reversion, while genetic factors and brain atrophy predict progression.

Area of Science:

  • Neuroscience
  • Gerontology
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) is a transitional state between normal aging and dementia.
  • Factors influencing MCI progression are known, but their role in cognitive reversal remains unclear.
  • Understanding MCI heterogeneity is crucial for early diagnosis and treatment.

Purpose of the Study:

  • To investigate factors associated with cognitive reversion in MCI.
  • To differentiate between progressive, reversible, and stable MCI subtypes.
  • To develop a prediction model for MCI outcomes.

Main Methods:

  • Analysis of 756 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with 36-month follow-up.
  • Comparison of demographic, lifestyle, clinical, cognitive, neuroimaging, and biomarker data across MCI subtypes (pMCI, rMCI, sMCI).
  • Development of a prediction model using multinomial regression.

Main Results:

  • Reversible MCI (rMCI) patients were younger and more educated than progressive MCI (pMCI) patients.
  • Memory, general cognition, daily function, and hippocampal volume distinguished all three MCI groups.
  • Higher education, larger hippocampal volume, and lower daily functional impairment predicted reversion; *APOE ε4*, poorer memory, and brain atrophy predicted progression (model accuracy: 78%).

Conclusions:

  • Hippocampal volume, education level, and daily functional activities are key indicators for assessing MCI disparities and predicting reversion.
  • Cognitive abilities and specific brain regions play differential roles in MCI reversal.
  • Findings advance the understanding of MCI heterogeneity and support precise diagnosis and treatment strategies.

Related Concept Videos

Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
752
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
498
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
523